Neurocrine Biosciences, Inc.· NBIX

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC

Continuum Advisory LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 99.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 418 shares of the company's stock after selling 43,650 shares during the period. Continuum Advisory LLC's holdings in Neurocrine Biosciences were

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge

RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'

Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord

H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Neurocrine price target raised to $210 from $207 at Piper Sandler

Neurocrine price target raised to $190 from $170 at Deutsche Bank